X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Caelum was acquired by AstraZeneca pursuant to the developing and commercializing biopharmaceutical products and product candidates cost-effectively including Caelum’s lead asset, CAEL-101, is a novel antibody for the treatment of patients with light chain (“AL”) amyloidosis.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $350.0 million Upfront Cash: $150.0 million
Deal Type: Acquisition October 06, 2021
Details:
AstraZeneca will accelerate ongoing Phase III clinical development of CAEL-101, a potential first-in-class medicine which is being evaluated in the Cardiac Amyloid Reaching for Extended Survival Phase III clinical programme in combination with standard-of-care therapy.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2021
Details:
An e-poster featuring the first data from a new arm of the study demonstrated that CAEL-101 administered in combination with cyclophosphamide-bortezomib-dexamethasone (CyBorD) plus daratumumab was generally safe and well-tolerated in the first four weeks of treatment.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis. Data, from Caelum, that further shows safety and tolerability of CAEL-101 and support the selection of the 1000 mg/m2 dose for the Phase 3 study will also be presented.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
